美国 · 平台与数据 · MarketBeat
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates…
在 MarketBeat 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)
